{"nctId":"NCT04106557","briefTitle":"A Study of OV101 in Individuals With Angelman Syndrome (AS)","startDateStruct":{"date":"2019-09-09","type":"ACTUAL"},"conditions":["Primary Disease or Condition Being Studied: Angelman Syndrome (AS)"],"count":104,"armGroups":[{"label":"OV101 once daily (weight-based dosing) Other Name:Gaboxadol","type":"EXPERIMENTAL","interventionNames":["Drug: Gaboxadol"]},{"label":"Placebo once daily","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Gaboxadol","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female and 2 to 12 years old (inclusive) at the time of informed consent\n* Confirmed molecular diagnosis of AS\n* Has a CGI-S-AS score of 3 or more at baseline.\n* Meets the following age-appropriate body weight criterion:\n\n  1. Subjects 2 to 3 years old must have a minimum body weight of 9 kg.\n  2. Subjects 4 years and older must be between 17 kg and 64 kg (inclusive).\n* Stable concomitant mediations for at least 4 weeks before study start\n\nExclusion Criteria:\n\n* Any condition that would limit study participation\n* Clinically significant lab or vital sign abnormalities at the time of screening\n* Poorly controlled seizures (weekly seizures of any frequency with a duration more than 3 minutes, weekly seizures occurring more than 3 times per week, each with a duration of less than 3 minutes, or as defined by investigator assessment)\n* Use of prescription medications for sleep, minocycline, or levodopa within the 4 weeks prior to Day 1 or during the study. Benzodiazepines chronically administered for seizure control are permitted.\n* Cannot comply with protocol study assessments during screening or caregiver unable to comply with study requirements.\n* Enrolled in any clinical trial or used any investigational agent within the 30 days before screening or concurrently with this study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"12 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Global Impressions- Improvement in Angelman Syndrome (CGI-I-AS) Rating at 12 Weeks","description":"To evaluate the efficacy of OV101 versus placebo as assessed by the Clinical Global Impressions-Improvement-Angelman syndrome (CGI-I-AS) score at Week 12. CGIA-I-AS scores range from 1 (very much improved), to 4 (no change), to 7 (very much worse).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":47},"commonTop":["Vomiting","Nasopharyngitis","Diarrhea","Seizure","Irritability"]}}}